Community based screening and treatment of Diabetes in India
Not Applicable
Active, not recruiting
- Conditions
- Health Condition 1: null- Screening for Diabetes and confirmed Diabetes MellitusHealth Condition 2: E119- Type 2 diabetes mellitus without complications
- Registration Number
- CTRI/2021/03/031619
- Lead Sponsor
- European Foundation for Study of Diabetes
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Closed to Recruitment of Participants
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Willing to Consent and agree to follow up for upto 6 months
Exclusion Criteria
Not willing to stay in the study area for the duration of the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways are targeted by m-health interventions in CTRI/2021/03/031619 for diabetes management?
How does the IMPACT Diabetes trial compare to standard-of-care treatments like metformin or SGLT2 inhibitors in Type 2 diabetes populations?
Which biomarkers are used in CTRI/2021/03/031619 to predict treatment response in community-based diabetes screening?
What adverse events are associated with m-health-led diabetes screening and treatment approaches in low-resource settings?
Are there combination therapies or competitor drugs (e.g., GLP-1 agonists) evaluated alongside the IMPACT Diabetes intervention in India?